Tumor infiltrating lymphocyte (TILs) therapy or tumor-derived autologous T cell immunotherapy is a form of immunotherapy that uses your body’s own immune cells to target and destroy cancer. It ...

Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due ...

Drug sensitivity patterns across FAB subtypes and molecular mutations in AML. Comparative safety and effectiveness of azacitidine plus venetoclax versus intensive chemotherapy in acute myeloid ...

Work described in this story was made possible in part by federal funding supported by taxpayers. At Harvard Medical School, the future of efforts like this — done in service to humanity — now hangs ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Adoptive cell therapy based ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines help ...

In general, increasing lymphocyte entry into tumor microenvironment (TME) and limiting their efflux will have a positive effect on the efficacy of immunotherapy. Current studies suggest maintenance ...

An expert discusses the patient case of a man aged 62 years who is newly diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The patient initially presented to the dermatologist with ...